Pharma quick ratio: expected band 1.5 to 3.0
Why pharmaceutical firms carry the highest quick ratios in the index, and what the R&D pipeline does to working capital.
A financially healthy pharmaceutical firm typically posts a quick ratio between 1.5 and 3.0. Long R&D cycles (often 7 to 12 years from discovery to approval), large accounts receivable from hospital and distributor customers, and substantial finished-goods inventory drive the largest working capital balances of any sector. Quick ratios above 2.0 are common for late-stage biotech firms holding trial-financing cash.
Verified June 2026. Source: Damodaran NYU Stern Working Capital dataset. US data, last update January 2026. Sector: Drugs (Pharmaceutical).
The numbers behind the band
| Working capital input | Pharmaceuticals | Why it matters |
|---|---|---|
| Inventory / Sales | 15.61% | Long shelf-life products and batch manufacturing keep stocks high. |
| AR / Sales | 21.80% | Hospital, insurer, and distributor terms run 60 to 120 days. |
| Non-cash WC / Sales | 32.09% | Highest in the index. Substantial cash is tied up in receivables and inventory. |
| Expected quick ratio | 1.5 to 3.0 | Boards target high liquidity to fund multi-year R&D pipelines. |
Verified June 2026. Source: Damodaran NYU Stern Working Capital dataset. Last update January 2026, US listed companies.
Pre-revenue biotech is a special case
Clinical-stage biotech firms with no commercial revenue routinely post quick ratios above 5.0. The balance sheet is dominated by IPO or follow-on financing cash held against operating expense, with minimal current liabilities. In that regime, the quick ratio measures runway rather than solvency: cash divided by quarterly burn yields the more relevant number.
A pre-revenue biotech with a quick ratio of 8.0 and 12 months of runway is materially weaker than a commercial-stage pharma with a quick ratio of 1.6 and recurring product sales.
When a pharma firm reads below the band
- Patent cliff approaching. Generic competition is about to compress AR and inventory. Boards often draw down cash for buybacks before the cliff.
- Large licensing milestone payment. One-off payments to academic licensors can sit in current liabilities for one or two quarters.
- Recent regulatory failure. FDA Complete Response Letter or EMA refusal can trigger inventory write-downs and a sudden quick-ratio fall.
Interpreting the ratio
How to read above-band and below-band quick ratios without falling for false signals.
12 sector bands
Pharma is the highest. Browse the other 11.